Braidwell LP Has $16.43 Million Stock Holdings in argenex SE $ARGX

Braidwell LP trimmed its holdings in argenex SE (NASDAQ:ARGX) by 79.2% during the second quarter, Holdings Channel reports. The institutional investor owned 17,707 shares of the company’s stock after selling 67,232 shares during the quarter. Braidwell LP’s holdings in argenex were worth $16,428,000 as of its most recent SEC filing.

A number of other hedge funds have also recently made changes to their positions in ARGX. Sands Capital Management LLC raised its holdings in shares of argenex by 2,046.6% in the 4th quarter. Sands Capital Management LLC now owns 356,870 shares of the company’s stock worth $300,110,000 after acquiring an additional 340,245 shares during the last quarter. Invesco Ltd. boosted its stake in argenex by 390.4% during the 4th quarter. Invesco Ltd. now owns 416,408 shares of the company’s stock valued at $350,178,000 after purchasing an additional 331,489 shares during the last quarter. Wellington Management Group LLP increased its holdings in argenex by 80.1% during the 3rd quarter. Wellington Management Group LLP now owns 729,986 shares of the company’s stock worth $538,408,000 after purchasing an additional 324,653 shares in the last quarter. Two Sigma Investments LP increased its holdings in argenex by 570.3% during the 3rd quarter. Two Sigma Investments LP now owns 294,160 shares of the company’s stock worth $216,961,000 after purchasing an additional 250,278 shares in the last quarter. Finally, Corient Private Wealth LLC raised its stake in shares of argenex by 12,441.8% in the fourth quarter. Corient Private Wealth LLC now owns 246,572 shares of the company’s stock worth $207,355,000 after purchasing an additional 244,606 shares during the last quarter. 60.32% of the stock is currently owned by institutional investors and hedge funds.

argenex Stock Up 2.6%

Shares of ARGX stock opened at $1,055.37 on Thursday. The company has a 50 day moving average of $920.25 and a 200-day moving average of $838.50. argenex SE has a 12-month low of $661.85 and a 12-month high of $1,072.75. The firm has a market cap of $66.02 billion, a P/E ratio of 40.53, a PEG ratio of 1.07 and a beta of 0.47.

argenex (NASDAQ:ARGX) last posted its quarterly earnings data on Tuesday, July 21st. The company reported $7.32 EPS for the quarter, beating the consensus estimate of $5.86 by $1.46. argenex had a return on equity of 43.59% and a net margin of 32.19%.The business had revenue of $1.54 billion for the quarter, compared to the consensus estimate of $1.45 billion. As a group, equities analysts expect that argenex SE will post 29.04 EPS for the current year.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on ARGX. Robert W. Baird raised their target price on argenex from $867.00 to $932.00 and gave the company a “neutral” rating in a report on Monday, July 27th. Royal Bank Of Canada upped their price target on argenex from $1,025.00 to $1,100.00 and gave the stock an “outperform” rating in a report on Tuesday, August 18th. Bank of America increased their price target on argenex from $1,016.00 to $1,088.00 and gave the company a “buy” rating in a research report on Thursday, July 2nd. Wall Street Zen upgraded argenex from a “hold” rating to a “buy” rating in a research note on Saturday, August 29th. Finally, Truist Financial lifted their price objective on shares of argenex from $1,030.00 to $1,095.00 and gave the stock a “buy” rating in a report on Tuesday, August 18th. Two research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and five have given a Hold rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $1,158.61.

About argenex

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.